Bevacizumab biosimilar(Bioxpress)

贝伐珠单抗生物类似药（Bioxpress）

Report date: 2022/03/16 14:40:25

Base Information

Drug NameBevacizumab biosimilar(Bioxpress)
Drug Alias Namebevacizumab biosimilar(Bioxpress)贝伐珠单抗生物仿制药（Bioxpress）贝伐单抗生物仿制药（Bioxpress）贝伐单抗生物类似药（Bioxpress）贝伐人源化单抗生物仿制药（Bioxpress） +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesBioxpress Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesBioxpress Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A